Inmune Bio Secures UK Regulatory Alignment for CORDStrom™ in RDEB, Paving Way for 2026 MAA
INMB sits 30% above its 52-week low of $1.09.
Summary
Inmune Bio received positive regulatory feedback from the UK MHRA for its CORDStrom™ drug in RDEB, establishing a clear path for a 2026 conditional market authorization application. This de-risks a key pipeline asset and is vital for the company's long-term prospects.
Key Events · Product Development and Regulatory · INMB
-
Regulatory Alignment Achieved
Inmune Bio received official meeting minutes from the UK MHRA, confirming written alignment on all questions for CORDStrom™ (Ebstrocel™) in Recessive Dystrophic Epidermolysis Bullosa (RDEB), covering CMC, non-clinical, and clinical evidence.
-
Clear Path to Market in UK
The regulatory alignment provides a clear roadmap for a planned 2026 UK Marketing Authorization Application (MAA) seeking Conditional Marketing Authorization for Ebstrocel™.
-
Clinically Meaningful Benefits Recognized
The MHRA recognized MissionEB Phase 2 data as demonstrating 'clinically meaningful symptomatic benefit,' particularly in pain and pruritus, for RDEB patients.
-
Guidance for Confirmatory Phase 3 and Future Submissions
MHRA provided constructive guidance on the confirmatory Phase 3 program, accepted capital-efficient non-clinical safety and manufacturing plans, and invited alternative statistical approaches for rare diseases. The company plans EU and US submissions in late 2026 or early 2027.
Analysis · INMB · Life Sciences
This 8-K announces that Inmune Bio has received official minutes from its pre-Marketing Authorization Application (pre-MAA) meeting with the UK MHRA, confirming alignment on all regulatory questions for CORDStrom™ (Ebstrocel™) in Recessive Dystrophic Epidermolysis Bullosa (RDEB). This provides a clear regulatory roadmap for a planned 2026 UK Conditional Marketing Authorization Application, significantly de-risking the path to market for this ultra-rare disease treatment. The MHRA's recognition of clinically meaningful symptomatic benefits from Phase 2 data is a strong positive signal, and the guidance on confirmatory trials and statistical approaches is constructive. This progress on a key pipeline asset is crucial for the company, especially given its previously disclosed going concern warning.
At the time of this filing, INMB was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.8M. The 52-week trading range was $1.09 to $11.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.